On December 4, 2025, Virax Biolabs Group Limited closed the transaction. The company paid $350,000 for placement agent fees, $50,000 for placement agent management fee, $35,000 for non-accountable expenses, $50,000 for legal expenses and issued warrants to purchase up to 875,000 ordinary shares. The company issued pre funded warrants and preferred option pursuant to exemption provided under Regulation D. The transaction included participation from 1 investor.

On April 10, 2026, the company announced that all Pre-Funded Warrants have been exercised, and the total number of the Company's ordinary shares outstanding is 19,923,432.